KR20220002316A - Cdk 억제제와 조합된 rank 경로 억제제 - Google Patents

Cdk 억제제와 조합된 rank 경로 억제제 Download PDF

Info

Publication number
KR20220002316A
KR20220002316A KR1020217034378A KR20217034378A KR20220002316A KR 20220002316 A KR20220002316 A KR 20220002316A KR 1020217034378 A KR1020217034378 A KR 1020217034378A KR 20217034378 A KR20217034378 A KR 20217034378A KR 20220002316 A KR20220002316 A KR 20220002316A
Authority
KR
South Korea
Prior art keywords
inhibitor
seq
rank
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217034378A
Other languages
English (en)
Korean (ko)
Inventor
코스타 루이스 안토니오 마르케스 다
안조 카시미로 산드라 크리스티나 카라 드
Original Assignee
인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스 filed Critical 인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스
Publication of KR20220002316A publication Critical patent/KR20220002316A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217034378A 2019-04-30 2020-04-24 Cdk 억제제와 조합된 rank 경로 억제제 Ceased KR20220002316A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840810P 2019-04-30 2019-04-30
PT115483 2019-04-30
PT11548319 2019-04-30
US62/840,810 2019-04-30
PCT/PT2020/050017 WO2020222668A1 (en) 2019-04-30 2020-04-24 Rank pathway inhibitors in combination with cdk inhibitors

Publications (1)

Publication Number Publication Date
KR20220002316A true KR20220002316A (ko) 2022-01-06

Family

ID=70775461

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034378A Ceased KR20220002316A (ko) 2019-04-30 2020-04-24 Cdk 억제제와 조합된 rank 경로 억제제

Country Status (9)

Country Link
US (1) US20220195059A1 (https=)
EP (1) EP3962945A1 (https=)
JP (1) JP2022530241A (https=)
KR (1) KR20220002316A (https=)
AU (1) AU2020266083A1 (https=)
BR (1) BR112021021663A2 (https=)
CA (1) CA3132656A1 (https=)
MX (1) MX2021013271A (https=)
WO (1) WO2020222668A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022272427A1 (en) * 2021-05-12 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN115718192B (zh) * 2022-11-25 2025-02-14 浙江洛兮医疗科技有限公司 一种免疫组化即用型pd-l1抗体试剂
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
PL369742A1 (en) 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
WO2004069137A2 (de) 2003-02-07 2004-08-19 Ge Bayer Silicones Gmbh & Co. Kg Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren
WO2004097048A1 (en) 2003-04-28 2004-11-11 Canon Kabushiki Kaisha Process for assay of nucleic acid by competitive hybridization using a dna microarray
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US11596642B2 (en) * 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2020222668A1 (en) 2020-11-05
JP2022530241A (ja) 2022-06-28
AU2020266083A1 (en) 2021-09-23
MX2021013271A (es) 2022-01-06
US20220195059A1 (en) 2022-06-23
EP3962945A1 (en) 2022-03-09
CA3132656A1 (en) 2020-11-05
BR112021021663A2 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
KR102940310B1 (ko) 항-nkg2a 항체 및 그의 용도
JP6637439B2 (ja) 抗ｏｘ４０抗体及び使用方法
CN102906117B (zh) 抗lrp6抗体
JP6702991B2 (ja) Ｔ細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
CN112424358B (zh) 与细胞粘附分子3结合的抗体
KR20220002316A (ko) Cdk 억제제와 조합된 rank 경로 억제제
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
KR20160146747A (ko) 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
KR20180083936A (ko) 조합 치료 및 그의 용도 및 방법
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
CN114980902A (zh) 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
CN108290947A (zh) 组合治疗及其用途和方法
CN114729049B (zh) 抗原结合蛋白
US20210324081A1 (en) Dosing
US20210395367A1 (en) Dosing
RU2827188C1 (ru) Антигенсвязывающие белки
HK40047612A (en) Antibody binding to cell adhesion molecule 3
HK40047612B (zh) 与细胞粘附分子3结合的抗体
HK1227043A1 (en) Anti-ox40 antibodies and methods of use
HK1242614A1 (en) Combination therapy comprising ox40 binding agonists and tigit inhibitors
HK1248122A1 (zh) 抗met抗體及其使用方法
HK1226956A1 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601